Subcutaneous Injection

Subcutaneous (SC) injection delivers a solution into the adipose tissue layer between the skin (dermis) and the muscle fascia. For peptides, this creates a drug depot: the peptide diffuses slowly from the injection site into surrounding capillaries and lymphatics, producing a sustained absorption profile.

Why subcutaneous is the default for peptides

Three factors make SC injection the preferred route:

1. Sustained absorption profile. The SC depot provides a slow, steady release into the bloodstream over 1–4 hours (depending on the peptide), avoiding the rapid spike-and-crash of intravenous delivery. This is pharmacologically desirable for GH-releasing peptides, BPC-157, and most research peptides
2. Practical self-administration. SC injection uses short, fine needles (29–31G, 12.7mm) that can be administered at home without medical training. Insulin syringes are inexpensive, widely available, and graduate in 0.5–1 unit increments
3. Adequate bioavailability. Most peptides achieve 60–80% bioavailability via SC, which is sufficient for therapeutic dosing. The remaining 20–40% is lost to local degradation by tissue peptidases and lymphatic uptake that leads to hepatic clearance

The pharmacokinetics of SC absorption

After SC injection, a peptide must traverse several barriers to reach the systemic circulation:

1. Diffusion from the depot. The injected solution forms a bolus in the subcutaneous tissue. Smaller peptides (<10 kDa) diffuse primarily into blood capillaries; larger molecules (>16 kDa) are preferentially absorbed via lymphatic vessels
2. Local proteolysis. Subcutaneous tissue contains peptidases that degrade a fraction of the dose before absorption. This "pre-systemic" loss contributes to the difference between IV and SC bioavailability
3. Capillary and lymphatic uptake. Blood flow to the injection site is the rate-limiting factor. Higher blood flow = faster absorption. This is why exercise, warm temperatures, and massage at the injection site all accelerate absorption

Peak plasma concentration (Cmax) after SC injection typically occurs at 1–4 hours, compared to seconds-to-minutes for IV. The time-to-peak varies by peptide molecular weight, formulation, and injection site.

Injection site pharmacokinetics

Not all injection sites are equal. Documented differences:

| Site | Relative absorption rate | Notes |

|---|---|---|

| Abdomen | Fastest SC absorption | Most consistent; standard for insulin and GLP-1 agonists |

| Outer thigh (vastus lateralis) | Moderate | Slower than abdomen; common alternative |

| Upper arm (posterior-lateral) | Moderate to fast | Difficult to self-inject; often used by clinicians |

| Buttock (upper outer quadrant) | Slowest SC absorption | Largest fat depot; useful for slow-release formulations |

For most peptide protocols, the abdomen (at least 2 inches from the navel) is the recommended site due to consistent absorption kinetics and ease of access.

Technique fundamentals

Equipment: insulin syringe, 29–31 gauge, 0.5-inch (12.7 mm) needle. For peptide doses < 0.5 mL, a 0.5 mL syringe provides better accuracy than a 1 mL syringe.

Preparation: wash hands. Clean the injection site with an alcohol swab and allow to air dry (10–15 seconds). Draw the desired dose from the reconstituted peptide vial using aseptic technique.

Injection:

1. Pinch a fold of skin and subcutaneous fat between thumb and forefinger
2. Insert the needle at a 45° angle (thin individuals with little SC fat) or 90° angle (normal-to-high body fat)
3. Release the pinch (optional — some protocols maintain the pinch throughout)
4. Inject the solution slowly and steadily over 5–10 seconds
5. Wait 5–10 seconds with the needle in place to prevent leakback
6. Withdraw the needle at the same angle as insertion
7. Apply gentle pressure with a clean swab — do not rub or massage

Aspiration (pulling back on the plunger to check for blood) is not recommended for SC injection. The risk of inadvertent intravascular injection at standard SC sites is negligible, and aspiration increases tissue trauma.

Site rotation

Repeated injection at the same location causes lipodystrophy — either lipoatrophy (fat loss, creating a dent) or lipohypertrophy (fat accumulation, creating a lump). Both alter local absorption kinetics, leading to unpredictable dosing.

Systematic rotation is essential for anyone injecting daily or more frequently:

• Divide the abdomen into quadrants or use a clock-face pattern
• Move at least 1 inch (2.5 cm) from the previous injection site
• Keep a simple log or use alternating sides (left/right) to track rotation
• Inspect injection sites regularly for signs of tissue changes

SC injection for specific peptide types

• GH-releasing peptides (ipamorelin, sermorelin, CJC-1295): inject on an empty stomach, typically in the morning or before bed. Abdominal SC. Food and especially carbohydrates blunt GH release
• BPC-157 and TB-500: some protocols inject SC near the injury site ("local" injection), though evidence that local vs. systemic injection differs in efficacy is limited for peptides that achieve systemic circulation
• GLP-1 agonists (semaglutide, tirzepatide): manufacturer-supplied auto-injector pens with pre-set doses. Any SC site (abdomen, thigh, upper arm). Once-weekly dosing
• Melanotan II and PT-141: abdominal SC. Low-volume injections (0.1–0.3 mL). Nausea is dose-dependent — slower injection may help